Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

l protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

FORWARD-LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securitie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
(Date:8/22/2014)... 265,000 Danes are acutely admitted to medical departments with ... and Aarhus University Hospital now shows that many of ... are sent home again without receiving a diagnosis of ... "Naturally, there is no need for a diagnosis if ... a serious illness. So some patients will always be ...
(Date:8/22/2014)... nurses at New York University,s Langone Medical Center (NYULMC) ... the youngest and most vulnerable down flights of stairs ... generated by Hurricane Sandy. , Now, a recent ... of Nursing (NYUCN) and of Dentistry (NYUCD), published in ... impact on NYULMC nurses, post-Sandy deployment to help address ...
(Date:8/22/2014)... August 22, 2014 Human induced pluripotent ... of regenerative medicine because they can be coaxed to ... always act as anticipated. They sometimes mutate, develop into ... a new study recently published in STEM CELLS Translational ... this, simply by removing the material used to reprogram ...
(Date:8/22/2014)... low levels of nicotine may reduce addiction without ... new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours of ... of cigarettes with markedly reduced nicotine levels. , ... of which have very similar levels of nicotine ...
(Date:8/22/2014)... 2014 Lincolnshire Marriott Resort is inviting ... a tap, announcing Marriott’s new iPad Mini promotion for ... this exclusive offer will receive a complimentary iPad Mini ... the day’s agenda with ease. Marriott’s Meeting Services app, ... and connect with their group with just a few ...
Breaking Medicine News(10 mins):Health News:Many patients are discharged without a diagnosis 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:Lincolnshire Marriott Resort Offers iPad Mini for Chicago Meeting Planners 2
... Oct. 5 "The good news is,that there ... Terry D. Hashey,Medical Director of First Coast Family ... Corral Flu Campaign. "The bad news,is that despite ... still,ranked below the national average of 69.3% for ...
... dietary supplement ... LipidShield Plus(TM), MELBOURNE, Fla., Oct. ... has expanded again and LipidShield Plus(TM) is,now available at Stop & ... breakthrough cholesterol,fighting product that has been clinically proven to lower cholesterol ...
... Oct. 5 /Xinhua-PRNewswire/ -- In a star-studded ... Olympics honored twelve,extraordinary individuals and the city ... made and continue to make to promote ... of people with intellectual,disabilities, and the Special ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... Calif., Oct. 4 The Integrated Healthcare,Association ... to physician,groups in California at its annual ... 47 most outstanding physician groups were,honored for ... care,quality measures, including preventive care and chronic ...
... HealthShares(TM) Inc., an investment,company with a series ... been informed by Standard & Poor,s, the calculating ... at the opening of,trading on October 8, 2007, ... (NasdaqGS: FOXH) in the,HealthShares(TM) Cardio Devices Index. ...
Cached Medicine News:Health News:Florida Health Care Community Stepping Up for the 2007-2008 Flu Season 2Health News:New Health Corp. Announces the Addition of Stop & Shop and Giant Supermarkets to its Retail Outlets 2Health News:Special Olympics 'Special Spirit in China Award Of Excellence' Presented to Dedicated Friends of Special Olympics and City of Shanghai 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 2Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 3Health News:California Physician Groups Recognized by Integrated Healthcare Association (IHA) 4Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Cardio Devices Index 3
... Novagen's Vacuum Manifold system for sample ... to which a vacuum is applied, a ... accessories for convenience in sample handling. The ... elution of up to 12 samples simultaneously. ...
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 6S;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: